Don't Count Voclosporin Ophthalmic Solution Out [Seeking Alpha]
Aurinia Pharmaceuticals Inc - Common Shares (AUPH)
Last aurinia pharmaceuticals inc - common shares earnings: 3/5 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.auriniapharma.com
Company Research
Source: Seeking Alpha
Summary Company and Disease Background Aurinia Pharmaceuticals ( AUPH ) is a small-cap ($437m) pharmaceutical company best known for its novel calcineurin inhibitor, Voclosporin, which is currently in phase III trials for Lupus Nephritis. Lupus Nephritis is potentially a $1-2 billion/year market and is presumably why most investors own stock in the company. However, a hidden gem in Aurinia's pipeline is its ophthalmic solution of this novel calcineurin inhibitor, which naturally goes by Voclosporin Ophthalmic Solution (VOS). VOS is being investigated as a potential treatment for Dry Eye Syndrome, a very common disease that affects 20 million patients in the US alone. (Source: Aurinia Pharmaceuticals Investor Presentation) After a phase I trial dose escalation found the drug to be safe and well tolerated, Aurinia has moved on to a larger phase II trial, where VOS will go head to head with the current standard of care, Restasis. Restasis is also a calcineurin
Show less
Read more
Impact Snapshot
Event Time:
AUPH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AUPH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AUPH alerts
High impacting Aurinia Pharmaceuticals Inc - Common Shares news events
Weekly update
A roundup of the hottest topics
AUPH
News
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor Conference [Yahoo! Finance]Yahoo! Finance
- UPDATE: New Aurinia Presentation Details at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceBusiness Wire
- Pelthos Therapeutics Establishes Board of Directors [Yahoo! Finance]Yahoo! Finance
- Aurinia Pharmaceuticals to Release First Quarter Financial and Operational Results on May 2, 2024Business Wire
- Aurinia Will Attend 2024 Bloom Burton & Co. Healthcare Investor ConferenceBusiness Wire
AUPH
Earnings
- 2/15/24 - Miss
AUPH
Sec Filings
- 3/20/24 - Form SC
- 3/7/24 - Form 4
- 3/7/24 - Form 4
- AUPH's page on the SEC website